Procaps Group, S.A. (PROC): Price and Financial Metrics

Procaps Group, S.A. (PROC): $2.99

0.28 (+10.33%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

B

Add PROC to Watchlist
Sign Up

PROC Price/Volume Stats

Current price $2.99 52-week high $5.00
Prev. close $2.71 52-week low $1.95
Day low $2.92 Volume 984
Day high $2.99 Avg. volume 20,636
50-day MA $3.07 Dividend yield N/A
200-day MA $3.43 Market Cap 337.33M

PROC Stock Price Chart Interactive Chart >


Procaps Group, S.A. (PROC) Company Bio


Procaps Group, S.A. develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and clinical solutions. It operates in 13 countries in Latin America. The company was founded in 1977 and is based in Luxembourg City, Luxembourg


PROC Latest News Stream


Event/Time News Detail
Loading, please wait...

PROC Latest Social Stream


Loading social stream, please wait...

View Full PROC Social Stream

Latest PROC News From Around the Web

Below are the latest news stories about PROCAPS GROUP SA that investors may wish to consider to help them evaluate PROC as an investment opportunity.

PROC Stock Earnings: Procaps Gr Beats EPS, Beats Revenue for Q3 2023

PROC stock results show that Procaps Gr beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023.

InvestorPlace Earnings on InvestorPlace | December 27, 2023

Procaps Group Reports Third Quarter 2023 Results

MIAMI & BARRANQUILLA, Colombia, December 26, 2023--Procaps Group Reports Third Quarter 2023 Results

Yahoo | December 26, 2023

Statement from the Board of Directors of Procaps Group

MIAMI & BARRANQUILLA, Colombia, December 21, 2023--Statement from the Board of Directors of Procaps Group

Yahoo | December 21, 2023

Procaps Group and Genomma Lab Announce a Strategic Agreement to Manufacture and Market Softgel Products in Latin America

Procaps Group (NASDAQ: PROC) ("Procaps"), a leading integrated international healthcare and pharmaceutical services company, and Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB; "Genomma"), the leading pharmaceutical and personal care company in Latin America, today announced a strategic agreement to develop, manufacture and market five Softgel products within Latin America. Through the partnership, Procaps will manufacture and Genomma will market and distribute the products.

Yahoo | November 30, 2023

Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024

MIAMI & BARRANQUILLA, Colombia, November 22, 2023--Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024

Yahoo | November 22, 2023

Read More 'PROC' Stories Here

PROC Price Returns

1-mo N/A
3-mo -29.15%
6-mo 0.34%
1-year -40.20%
3-year N/A
5-year N/A
YTD -26.54%
2023 -22.48%
2022 -46.15%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!